|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most significant finding (nominal P = 0.0004; false discovery rate q = 0.037) was a combined genotype association across IKBKB SNP rs5029748 (1 or 2 variant alleles), IL6 rs1800797 (1 or 2 variant alleles), and NFKB1 rs4648110 (2 variant alleles) which conferred an ~80% decreased risk of colon cancer.
|
21129206 |
2010 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MSI in colon cancer is linked to a significant increase of immunocompetent cells responsible for the antitumor activity - CD3(+), CD8(+), CD45RO(+), and T-bet(+) lymphocytes and decrease of inhibition factors such as Foxp3, IL-6, IL-17, and TGF-β.
|
27372860 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
|
15485627 |
2004 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IL-6 therapeutics are available for treating colon cancer; however, they are expensive and induce negative side effects.
|
28193578 |
2017 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fermented Herbal Formulas KIOM-MA128 Ameliorate IL-6-Induced Intestinal Barrier Dysfunction in Colon Cancer Cell Line.
|
27980357 |
2016 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, we further demonstrated that overexpressing PHD2 attenuated inflammation in colon cancer xenograft mice through weakening accumulation of myeloid-derived suppressor cells (MDSCs) and M2-like tumor-associated macrophages (TAMs), as well as secretions of pro-inflammatory cytokines including G-CSF, TNF-α, IL-6, IL-8, IL-1β, and IL-4.
|
31838134 |
2020 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively.
|
12349828 |
2002 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis.
|
22738913 |
2012 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.
|
10903137 |
2000 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We cocultured colon cancer cell lines (HCT8 or HCT116) with human myeloid leukemia mononuclear cells (THP-1) and found that interleukin-6 and interleukin-1β levels were reduced, and instead, interleukin-10 and Arginase-1 levels were elevated, suggesting that colon cancer cells contributed to M2 polarization of THP-1.
|
31088266 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anchorage-independent growth and migration of colon cancer cells was also increased by IL-6 in a 5-azadeoxycytidine-sensitive manner.
|
20354000 |
2010 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The resulting HIF-1α/miR-338-5p/IL-6 feedback loop was necessary for drug resistance in colon cancer cell lines.
|
31208913 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report evidence on the role of interleukin 6 (IL-6) in affecting pro-survival pathways in colon cancer progression, modulating the expression and the molecular interactions among the pro-apoptotic factor Bax, the DNA repair proteins Ku70/86 and Clusterin isoforms.
|
19177010 |
2009 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of IL-6 trans-signaling therefore offers a new therapeutic window downstream of the EGF-R for the treatment of colon cancer and possibly of other EGF-R related neoplastic diseases.
|
31694340 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that IL6, a proinflammatory cytokine produced in tumor-bearing states, promoted the metastatic colonization of colon cancer cells in association with dysfunctional antitumor immunity.
|
31554639 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
|
25625841 |
2015 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-6 is up-regulated in colon cancer tissue at the transcriptional level and is significantly associated with increased risk of relapse.
|
25862884 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape.
|
31150612 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notch, EGFR/ErbB, IL-6/sIL-6R) help control intestinal injury/regenerative responses and may drive intestinal inflammation and colon cancer initiation and progression.
|
28739265 |
2017 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.
|
26209639 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed that IL-6 and integrin ανβ6 are indicators of cancer progression and poor prognosis in patients with colon cancer.
|
30982362 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study examined the influence of paracrine IL-6 signaling on prostate tumor growth using allograft models of mouse prostate cancer (TRAMP-C2), colon cancer (MC38), and melanoma (B16) cell lines in wildtype (WT) and IL-6 knockout (IL-6<sup>-/-</sup> ) mice.
|
30345534 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined whether RPTS influences the interleukin-6 (IL-6)/Janus kinase (JAK)-signal transducer and activator of transcription-3 (STAT3) apoptosis molecular pathway and looked for colon cancer-related signal transduction pathways or targets inducing apoptosis.
|
26125778 |
2015 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used recombinant sgp130Fc protein and recently generated transgenic mice expressing high levels of sgp130Fc to discriminate between classic and trans-signaling in vivo, and demonstrated that IL-6 trans-signaling is critically involved in generation and maintenance of several inflammatory and autoimmune diseases including chronic inflammatory bowel disease, rheumatoid arthritis, peritonitis and asthma, as well as inflammation-induced colon cancer.
|
21145125 |
2011 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth hormone increased SHP-2/glycoprotein 130 binding and reduced interleukin 6-dependent STAT3 activation in the T84 human colon carcinoma and Jurkat human T-cell leukemia lines.
|
16012947 |
2005 |